Contents

Issue 125 • December 2022

In association with

In association with

What Rishi Sunak can do for the UK pharma industry 

Amidst a swap in UK leadership, the pharmaceutical industry hopes Rishi Sunak will free up funding and boost the economy

IN DEPTH

Inside the European mass shift to data-driven health solutions

Comment

GSK speeds up the race to market first RSV vaccine for older adults

Briefing

Industry news

Pharma industry briefing

Comment

GSK speeds up the race to market first RSV vaccine for older adults

Biden’s directive on foreign biotech investments impacts manufacturers

Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data

‘Twindemic’ risks warrant immediate steps in Europe and the US

A game of two halves for Roche’s recently approved wet AMD assets

In Depth

What Rishi Sunak can do for the UK pharma industry

Inside the European mass shift to data-driven health solutions

Chronic drug shortages signal difficult outlook for cardiovascular care

Can gene therapies for haemophilia defend their high price tags?

Trial termination analysis unveils a silver lining for patient recruitment

New dawn for the EU's joint procurement crisis response 

In Data

The pharma industry found it easier to fill AI vacancies in Q3 2022

Internet of things hiring levels in the pharma dropped in October 2022

Artificial intelligence hiring levels in pharma dropped in October 2022

11/23/2022 21:27:20
  • Home | What Rishi Sunak can do for the UK pharma industry
  • In this issue
  • Contents
  • CSafe
  • Tripletree
  • Briefing
  • Industry news
  • The pharma industry briefing
  • BEA Technologies
  • Mimotopes Company Insight
  • Mimotopes
  • Comment
  • GSK speeds up the race to market first RSV vaccine for older adults
  • Biden’s directive on foreign biotech investments impacts manufacturers
  • Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
  • ‘Twindemic’ risks warrant immediate steps in Europe and the US
  • A game of two halves for Roche’s recently approved wet AMD assets
  • Dr. Paul Lohmann
  • Nipro
  • In Depth
  • What Rishi Sunak can do for the UK pharma industry
  • Inside the European mass shift to data-driven health solutions
  • Chronic drug shortages signal difficult outlook for cardiovascular care
  • Can gene therapies for haemophilia defend their high price tags?
  • Trial termination analysis unveils a silver lining for patient recruitment
  • New dawn for the EU's joint procurement crisis response
  • Skyepharma
  • Bio Image Systems Inc.
  • In Data
  • The pharma industry found it easier to fill AI vacancies in Q3 2022
  • Internet of things hiring levels in the pharma dropped in October 2022
  • Artificial intelligence hiring levels in the pharma dropped in October 2022
  • Baxter
  • Events
  • Next issue